CTOs on the Move

Tricida

www.tricida.com

 
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), including a successful 135-subject, ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.tricida.com
  • 7000 Shoreline Court Suite 201
    South San Francisco, CA USA 94080
  • Phone: 415.429.7800

Executives

Name Title Contact Details
Wilhelm Stahl
 Chief Technology Officer Profile

Funding

Tricida raised $55M on 07/26/2016
Tricida raised $57.5M on 11/08/2017
Tricida raised $100M on 03/02/2018

Similar Companies

Absolute Biotech

Absolute Biotech is a company that specializes in antibody reagents, kits, and services, adding value to existing antibodies through annotation, validation, sequencing, engineering, and recombinant manufacturing.

Medical Security Card Company

Medical Security Card Company is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harpoon Therapeutics

Harpoon Therapeutics is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that harness the power of the body`s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient`s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. Harpoon`s third proprietary technology platform, extended release TriTAC-XR, is designed to mitigate cytokine release syndrome.

Advanced Recovery Systems

Find a rehab center to treat your drug or alcohol addiction, eating disorder, or mental illness. Connect with us and get help for your addiction.

Wraser Pharmaceuticals

Wraser Pharmaceuticals is a Ridgeland, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.